IBT is a leading development company that will provide novel therapies influencing the human infant microbiome to prevent or treat diseases. 


The developing microbiome of the newborn infant is more dynamic than that of the mature human. Medical needs in premature infants are huge since they are the most vulnerable humans on the planet and for them to survive, grow and thrive they need intensive and specialized care. Although advances in medical care and handling over the last 30 years have improved survival and well-being of these sensitive infants, both in the immediate post-natal period and in their subsequent lives, current drugs and therapies are mostly designed for adults and are not adapted to this specific, divergent and vulnerable patient population. Specific treatments and prophylactic therapies are thus underdeveloped and there is an urgent demand for drugs designed for the unique needs of the premature infant.



IBT identifies areas of high unmet medical need in premature infants and effectively develops innovative therapies.

IBT is, thanks to its well-developed networking, close to the needs expressed by neonatologists and parents to provide novel and satisfactory therapeutic solutions and continuously improve its offerings. Using its extensive experience in live bacterial therapeutics, IBT develops, and brings to market therapies in accordance with all applicable pharmaceutical regulations to satisfy the unmet medical needs of the premature infants. IBT strives to conduct effective and smart drug development to launch convenient, suitable, and effective drugs that offer solutions to the needs of premature infants.